KeyCorp Forecasts Strong Price Appreciation for Encompass Health (NYSE:EHC) Stock

Encompass Health (NYSE:EHC) had its price objective raised by KeyCorp from $117.00 to $120.00 in a report published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Other analysts also recently issued research reports about the company. Barclays upped their price target on Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday. Royal Bank of Canada increased their price target on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Truist Financial restated a “buy” rating and issued a $116.00 price objective (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. StockNews.com lowered shares of Encompass Health from a “buy” rating to a “hold” rating in a research note on Friday. Finally, William Blair reissued an “outperform” rating on shares of Encompass Health in a research report on Friday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Encompass Health has an average rating of “Buy” and an average target price of $107.67.

Encompass Health Trading Down 1.2 %

NYSE:EHC opened at $98.66 on Monday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. The company has a market capitalization of $9.94 billion, a P/E ratio of 22.12, a P/E/G ratio of 1.18 and a beta of 0.90. The stock’s 50 day moving average price is $96.20 and its 200 day moving average price is $95.35. Encompass Health has a 52 week low of $72.38 and a 52 week high of $104.55.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 18.06%. On average, research analysts forecast that Encompass Health will post 4.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Encompass Health

Hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers lifted its position in shares of Encompass Health by 5.7% in the 2nd quarter. Cetera Investment Advisers now owns 12,353 shares of the company’s stock worth $1,060,000 after acquiring an additional 664 shares during the period. CWM LLC raised its stake in shares of Encompass Health by 27.8% in the third quarter. CWM LLC now owns 8,164 shares of the company’s stock valued at $789,000 after purchasing an additional 1,776 shares in the last quarter. UMB Bank n.a. lifted its position in Encompass Health by 387.7% in the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after purchasing an additional 252 shares during the period. CHICAGO TRUST Co NA acquired a new stake in Encompass Health during the third quarter worth $221,000. Finally, Oliver Luxxe Assets LLC increased its holdings in Encompass Health by 43.7% in the 3rd quarter. Oliver Luxxe Assets LLC now owns 60,553 shares of the company’s stock valued at $5,852,000 after buying an additional 18,407 shares during the period. Institutional investors own 97.25% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.